Section Arrow
Quote
BEAM.NASDAQ
- Beam Therapeutics
Quotes are at least 15-min delayed:2025/09/04 04:01 EDT
Pre Market
Last
 18.81
+0.05 (+0.27%)
Bid
18.75
Ask
19
High 19.18 
Low 18.81 
Volume 106 
Regular Hours
Last
 18.76
+2.45 (+15.02%)
Day High 
20.22 
Prev. Close
16.31 
1-M High
19.425 
Volume 
8.60M 
Bid
18.75
Ask
19
Day Low
16.52 
Open
16.75 
1-M Low
15.6 
Market Cap 
1.65B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 16.45 
20-SMA 17.05 
50-SMA 18.64 
52-W High 35.25 
52-W Low 13.525 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.50/-3.91
Enterprise Value
1.80B
Balance Sheet
Book Value Per Share
10.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
63.52M
Operating Revenue Per Share
0.81
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
Pre Market -- -- --
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
Pre Market 0.0572 +0.0046 +8.75%
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
Pre Market 0.3497 -0.0202 -5.46%
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
Pre Market 2.49 -0.03 -1.19%
STTKShattuck Labs1.28+0.27+26.73%-- 
Pre Market 1.25 -0.03 -2.34%
Quotes are at least 15-min delayed：2025/09/04 04:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.